CTKB — Cytek Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $807.33m
- $540.66m
- $193.02m
- 78
- 22
- 50
- 48
Annual cashflow statement for Cytek Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -16.8 | 19.4 | 3.03 | 2.48 | -12.1 |
| Depreciation | |||||
| Non-Cash Items | 1.61 | 2.68 | 8.72 | 22.7 | 21.6 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.16 | -7.54 | -8.36 | -39.9 | -10.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -13.7 | 15.2 | 4.63 | -12.2 | 5.28 |
| Capital Expenditures | -0.973 | -1.55 | -4.36 | -9.87 | -4.83 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | -16.6 | -46 | -89.1 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.973 | -1.55 | -21 | -55.9 | -93.9 |
| Financing Cash Flow Items | — | — | — | -0.209 | -0.419 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.093 | 123 | 214 | 5.51 | -41.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -14.7 | 136 | 198 | -65.1 | -132 |